Picture of Rocket Pharmaceuticals logo

RCKT Rocket Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Momentum

Relative Strength (%)
1m-7.34%
3m-17.54%
6m+10.53%
1yr+21.43%
Volume Change (%)
10d/3m+3.93%
Price vs... (%)
52w High-16.34%
50d MA-4.32%
200d MA+20.09%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-50.14%
Return on Equity-50.01%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Rocket Pharmaceuticals EPS forecast chart

Profile Summary

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
July 7th, 1999
Public Since
February 18th, 2015
No. of Shareholders
32
No. of Employees
268
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
90,504,248

RCKT Share Price Performance

Upcoming Events for RCKT

Q1 2024 Rocket Pharmaceuticals Inc Earnings Release

Rocket Pharmaceuticals Inc Annual Shareholders Meeting

Q2 2024 Rocket Pharmaceuticals Inc Earnings Release

Similar to RCKT

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Abivax SA logo

Abivax SA

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

Picture of Acrivon Therapeutics logo

Acrivon Therapeutics

us flag iconNASDAQ Global Market

Picture of Adagene logo

Adagene

us flag iconNASDAQ Global Market

FAQ